Chondroitin Sulfate
Half-Life (t½) PO: 15h
Formula C13H21NO15S
Molecular Weight 463.37 g/mol
Aliases Chondroitin 4-sulfate, CS Pharmacological Mechanism Sulfated GAG of alternating glucuronic acid + N-acetylgalactosamine. Major cartilage matrix component. Oral CS → small fragments absorbed (~10% F) → proposed to accumulate in synovium + inhibit IL-1β-driven MMP + aggrecanase activity. Modest symptomatic OA benefit in meta-analyses; structural disease modification debatable. EU Rx in some countries.
Half-Life & Elimination Curve (PO: 15h) 100% 50% 25% 12.5% 0% 0h 0×t½ 15h 1×t½ 30h 2×t½ 45h 3×t½ 60h 4×t½ 3.1d 5×t½ 0×t½ (0h): 100% remaining 1×t½ (15h): 50% remaining 2×t½ (30h): 25% remaining 3×t½ (45h): 12.5% remaining 4×t½ (60h): 6.3% remaining 5×t½ (3.1d): 3.1% remaining Plasma (PO) t½ Decay (15h)
0×t½ 0h 100% 1×t½ 15h 50% 2×t½ 30h 25% 3×t½ 45h 12.5% 4×t½ 60h 6.3% 5×t½ 3.1d 3.1% Dosing Guidelines Oral (PO): Typical 933 mg (Range: 800–1200 mg)Pharmacokinetic Parameters Oral (PO): Bioavailability (F): 10% · Absorption (ka): 1.91 h⁻¹ (t½ka ≈ 22m) [PMID 12359162 ]Pathways It Modulates Target Organ Systems Musculoskeletal System Immune & Hematologic Interactions Glucosamine (synergistic): Canonical pairing in most OA clinical trials (GAIT).Chemical Structure & Identifiers InChIKey: KXKPYJOVDUMHGS-OSRGNVMNSA-NSMILES: CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1O)OS(=O)(=O)O)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)OReferences Directory Compounds Registry Human Biology Hub